Affiliation of authors: Department of Pathology, Columbia University Medical Center, New York, NY
Correspondence to: Vundavalli V. Murty, PhD, Department of Pathology, College of Physicians & Surgeons of Columbia University, 630 West 168th St., New York, NY 10032 (e-mail: vvm2{at}columbia.edu).
Feng et al. (1) examined whether changes in DNA methylation of 20 genes, selected on the basis of their role in cervical cancer, could be used as markers of cervical intraepithelial neoplasia (CIN) and invasive cervical cancer (ICC). The authors found varying frequencies of promoter hypermethylation in these 20 genes in 319 exfoliated cell samples and matched tissue biopsy specimens. For four of these genes (DAPK1, RARB, TWIST1, and CDH13), increasing frequency of hypermethylation was statistically significantly associated with increasing severity of disease. The estimated specificity of the three-gene panel (DAPK, RARB, and TWIST1) was 95%, which is higher than specificities reported for cytology and human papillomavirus (HPV) testing (1). Although the study was well designed and a molecular genetic test with high specificity such as this one is needed, some of the findings are inconsistent with previously reported results and the conclusions may therefore not be valid.
We believe that the following points are important to consider when interpreting the results of Feng et al. First, the high frequency of hypermethylation in the SFN, HIC1, and APC genes observed in the samples of histologically normal cells and atypical squamous cells of undetermined significance (ASCUS) is unusual. Although low frequency of methylation in a group consisting of ASCUS compared with CIN and ICC is not unexpected because of the diagnostic dilemma involved in classifying these cytologic changes into specific diagnostic categories, none of the previous studies reported such a high frequency of promoter hypermethylation for HIC1 and APC in normal cervical epithelium or other normal tissues (25). In fact, in our series of normal and ASCUS (N = 59) and ICC (N = 82) specimens, we observed a different pattern of promoter hypermethylation in these two genes. That is, we saw promoter hypermethylation in 4% and 0% of the normal/ASCUS group and 18.3% and 11% in ICC for HIC1 and APC genes, respectively. Similarly, the authors reported a higher frequency of promoter hypermethylation of SFN than has been seen in previous studies (6,7). Misclassification of methylation could occur due to amplification of nonspecific targets in the genome, which ultimately makes the results on these three genes difficult to interpret. Whether these genes have utility in cervical cancer screening needs to be confirmed in other studies.
A number of previous studies have also shown a high frequency of promoter hypermethylation of DAPK, CDH1, RARB, and p16 in ICC (24). However, the frequency of promoter hypermethylation of these genes in CIN lesions was not well studied. Thus, well-designed studies of CIN are required to determine whether inclusion of additional genes, such as HIC1, to the three-gene panel proposed by Feng et al. might improve its sensitivity in detecting high-risk lesions that progress.
In the context of previously published studies and our series, it is premature to propose a panel of genes that would be the best for screening CIN3/CIS and ICC or for identifying high-risk CIN. Before such a test based on promoter hypermethylation can be proposed for screening cervical cancer, further studies are required on a larger series of specimens from different geographical populations, and these studies should carefully address the issue of false-positive rates.
REFERENCES
(1) Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, Dembele B, Critchlow CW, Xi L, Lu H, McIntosh MW, Young AM, Kiviat NB. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005;97:27382.
(2) Dong SM, Kim HS, Rha SH, Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001;7:19826.
(3) Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2003;2:24.[CrossRef][Medline]
(4) Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001;7:5849.
(5) Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Gonzalez S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB, Herman JG. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:436671.
(6) Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. High frequency of hypermethylation at the 1433 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 2000;97:604954.
(7) Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 1433 sigma (stratifin) is an early event in breast cancer. Oncogene 2001;20:334853.[CrossRef][ISI][Medline]
Response to this Correspondence
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |